Pharmaceuticals

  • Read more: TOMORROW, 11/9! Book Launch: Specimen Science – Ethics and Policy Implications
    Article

    TOMORROW, 11/9! Book Launch: Specimen Science – Ethics and Policy Implications

    Book Launch: Specimen Science: Ethics and Policy Implications November 9, 2017 12:00 PM Countway Library, Lahey Room Harvard Medical School, Boston, MA In September 2017, MIT Press will publish Specimen Science: Ethics and Policy Implications, co-edited by Holly Fernandez Lynch (outgoing Petrie-Flom Executive Director), Barbara Bierer, I. Glenn Cohen (Faculty Director), and Suzanne M. Rivera. This edited volume stems from a conference in 2015 that brought…

  • Read more: REGISTER NOW (12/12)! Sixth Annual Health Law Year in P/Review
    Article

    REGISTER NOW (12/12)! Sixth Annual Health Law Year in P/Review

    Health Law Year in P/Review December 12, 2017 8:30 AM – 5:00 PM Wasserstein Hall, Milstein East AB Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Register for this event The Sixth Annual Health Law Year in P/Review symposium will feature leading experts discussing major developments during 2017 and what to watch out for in 2018. The…

  • Read more: Book Launch: Specimen Science: Ethics and Policy Implications
    Article

    Book Launch: Specimen Science: Ethics and Policy Implications

    Book Launch: Specimen Science: Ethics and Policy Implications November 9, 2017 12:00 PM Countway Library, Lahey Room Harvard Medical School, Boston, MA In September 2017, MIT Press will publish Specimen Science: Ethics and Policy Implications, co-edited by Holly Fernandez Lynch (outgoing Petrie-Flom Executive Director), Barbara Bierer, I. Glenn Cohen (Faculty Director), and Suzanne M. Rivera. This edited volume stems from a conference in 2015 that brought…

  • Read more: Errors in Patent Grants: More Common in Medical Patents
    Article

    Errors in Patent Grants: More Common in Medical Patents

    By James Love Recently I have become interested in the frequency of a “certificate of correction” on a granted patent, after two efforts to establish federal rights in patents granted. The first case involved the University of Pennsylvania.  We had identified five patents on CAR T technologies granted to five inventors from the University of…

  • Read more: The Cost of Medications: Current Realities and the Future of Pharmaceutical Pricing Regulations in the United States
    Article

    The Cost of Medications: Current Realities and the Future of Pharmaceutical Pricing Regulations in the United States

    The Cost of Medications: Current Realities and the Future of Pharmaceutical Pricing Regulations in the United States October 4, 2017 12:00 PM Wasserstein Hall, Milstein East B (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA From “Pharma Bro” Martin Shkreli to huge price jumps for the EpiPen to the Hepatitis C treatment that costs…

  • Read more: Orphan Drugs Designations and Approvals have Something to Say about Risks
    Article

    Orphan Drugs Designations and Approvals have Something to Say about Risks

    By James Love  This brief essay examines data from the U.S. Orphan Drug Act, including specifically the FDA designations of an indication for a drug to treat an orphan disease, and the likelihood that once the designation is made, the FDA will approve the drug for that indication. This is one empirical measure of the…

  • Read more: The U.S. Drug Price Catastrophe and the Central Planner
    Article

    The U.S. Drug Price Catastrophe and the Central Planner

    By Aobo Dong If you are fortunate enough to have an insurance plan with extensive coverage and low co-pays for prescription drugs, chances are you may not be overly concerned with the U.S. drug price catastrophe. For millions of Americans without such a plan, getting the much-needed prescribed medicine often involves frustrating multi-player exchanges between…

  • Read more: “The real possibility of an AIDS-free generation:” HIV Prevention and the Internet
    Article

    “The real possibility of an AIDS-free generation:” HIV Prevention and the Internet

    By Clíodhna Ní Chéileachair Last November, the National Health Executive (NHS) in the UK lost an appeal in the UK Court of Appeal regarding their failure to fund PrEP for individuals at risk of contracting HIV. PrEP, or Pre-Exposure Prophylaxis is a common term for regimes of anti-viral medication taken by individuals to lower their…

  • Read more: The Cost of Medications: Current Realities and the Future of Pharmaceutical Pricing Regulations in the United States
    Article

    The Cost of Medications: Current Realities and the Future of Pharmaceutical Pricing Regulations in the United States

    The Cost of Medications: Current Realities and the Future of Pharmaceutical Pricing Regulations in the United States October 4, 2017 12:00 PM Wasserstein Hall, Milstein East B (2036) Harvard Law School  From “Pharma Bro” Martin Shkreli to huge price jumps for the EpiPen to the Hepatitis C treatment that costs $1000 per pill, pharmaceutical pricing…

  • Read more: Perspectives on Cancer Drug Development Costs in JAMA
    Article

    Perspectives on Cancer Drug Development Costs in JAMA

    By James Love Vinay Prasad and Sham Mailankody’s JAMA Internal Medicine study on the costs of research and development (R&D) when bringing a single cancer drug to market has sparked renewed discussion about how to measure R&D costs as well as the relationship between R&D costs and prices. What follows is my perspective on the…